Dianthus is a highly capitalized clinical biotech with asymmetric upside if claseprubart proves its differentiated complement profile in late-stage autoimmune trials.
Overview
Dianthus Therapeutics is a pre-revenue clinical-stage biotech developing next-generation complement and immune therapies for severe autoimmune diseases. Its lead asset, claseprubart, selectively targets active C1s to suppress classical complement damage while preserving other immune defense pathways, potentially avoiding C5 inhibitor safety burdens. The company’s commercial promise rests on convenient low-volume autoinjector dosing, large neuromuscular markets, and global clinical execution. Revenue is currently limited to licensing and collaboration arrangements, but the pipeline could support multi-billion-dollar peak sales if late-stage trials succeed.